Portuguese Ministry Of Health Approves VAZKEPA For National Reimbursement To Reduce Cardiovascular Risk In High-Risk Patients; Eighth National Reimbursement In Europe; Amarin To Begin Commercialization In Portugal On August 1, 2024
Portfolio Pulse from Benzinga Newsdesk
The Portuguese Ministry of Health has approved VAZKEPA for national reimbursement to reduce cardiovascular risk in high-risk patients. This marks the eighth national reimbursement in Europe. Amarin will begin commercialization in Portugal on August 1, 2024.
July 17, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin's VAZKEPA has been approved for national reimbursement in Portugal, marking the eighth such approval in Europe. This is expected to positively impact Amarin's revenue as commercialization begins on August 1, 2024.
The approval for national reimbursement in Portugal is a significant milestone for Amarin, as it expands the market for VAZKEPA in Europe. This is likely to boost revenues starting from August 1, 2024, when commercialization begins.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100